🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

951 results for “Eli” Clear

  1. TAK-881

    Takeda

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

    phase 3 mab active

    1 trial

  2. TAK-881, HyQvia 100 mg/mL solution for infusion for subcutaneous use, HyQvia 100 mg/mL solution for infusion for subcutaneous use

    Takeda

    Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  3. TAMOXIFEN , EXEMESTANE , ANASTROZOLE , LETROZOLE , Verzenios 50 mg film-coated tablets

    Eli Lilly Co.

    Breast Cancer

    phase 3 small molecule active

    1 trial

  4. TAMOXIFEN, LETROZOLE, ANASTROZOLE, FULVESTRANT, LEUPRORELIN, OXYBUTYNIN, GOSERELIN, VENLAFAXINE, LEUPRORELIN, GOSERELIN, EXEMESTANE, VENLAFAXINE

    Shanghai Reinovax Biologics Co.,LTD

    Breast cancer

    phase 3 small molecule active

    1 trial

  5. TARA-002

    Protara Therapeutics

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 3 small molecule active

    1 trial

  6. TIRZEPATIDE, TIRZEPATIDE, Retatrutide, Retatrutide, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, Retatrutide, Retatrutide, TIRZEPATIDE, Placebo to match LY, Retatrutide, Placebo to match LY

    Eli Lilly Co.

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 3 small molecule active

    1 trial

  7. TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, Placebo to match LY3298176, TIRZEPATIDE, TIRZEPATIDE

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  8. TLX-101-Tx + Lomustine

    Telix Innovations

    Neoplastic Disease

    phase 3 other active

    1 trial

  9. TOOKAD 183 mg powder for solution for injection, PADELIPORFIN

    STEBA Biotech S.A

    Low Grade Upper Tract Urothelial Cancer

    phase 3 small molecule active

    1 trial

  10. TOPOTECAN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE, PACLITAXEL, KEYTRUDA 25 mg/mL concentrate for solution for infusion, NEMVALEUKIN ALFA, GEMCITABINE HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

    Wuhan Createrna Science and Technology Co., Ltd

    Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    phase 3 small molecule active

    1 trial

  11. TRASTUZUMAB, Tislelizumab, Oxaliplatin 5 mg/ml concentrate for solution for infusion, LOPERAMIDE, JZP598, CAPECITABINE

    Jazz Pharmaceuticals Ireland Limited

    Gastroesophageal Adenocarcinoma (GEA)

    phase 3 small molecule active

    1 trial

  12. TROPICAMIDE, Vehicle for cenegermin drug product, COLIROFTA ANESTÉSICO DOBLE 1 MG/ML + 4 MG/ML COLIRIO EN SOLUCIÓN, OXERVATE 20 micrograms/ml eye drops, solution

    Dompe' Farmaceutici S.p.A.

    Persistent Corneal Epithelial Defect (PCED)

    phase 3 small molecule active

    1 trial

  13. Tadalafil

    Eli Lilly and Company

    Hypertension, Pulmonary

    phase 3 small molecule completed

    1 trial

  14. Taselisib

    Hoffmann-La Roche

    Breast Cancer

    phase 3 small molecule terminated

    1 trial

  15. Tasisulam-sodium

    Eli Lilly and Company

    Melanoma

    phase 3 small molecule terminated

    1 trial

  16. Telisotuzumab Adizutecan

    AbbVie

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  17. Telisotuzumab Vedotin, DOCETAXEL

    AbbVie Deutschland GmbH & Co. KG

    c-Met overexpressing EGFR wildtype non-squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  18. Telitacicept

    Vor Biopharma

    Primary Sjogren's Disease

    phase 3 mab active

    1 trial

  19. Telitacicept

    Vor Biopharma

    Systemic Lupus Erythematosus

    phase 3 mab terminated

    2 trials

  20. Telitacicept

    Vor Biopharma

    Generalized Myasthenia Gravis

    phase 3 mab active

    1 trial

  21. Teriparatide

    Eli Lilly and Company

    Femur Neck Fracture

    phase 3 small molecule completed

    1 trial

  22. Testosterone MD-Lotion

    Eli Lilly and Company

    Hypogonadism

    phase 3 small molecule completed

    1 trial

  23. Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age

    Sinovac Research and Development Co.,

    Poliomyelitis

    phase 3 mab completed

    1 trial

  24. Tinlarebant 5 mg´s matching Placebo, LBS-008

    ELITE PHARMACEUTICALS INC /NV/

    Stargardt Disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources